Silo Pharma Announces It Has Advanced The Formulation Development Of SPC-15; Liquid Nasal Formulation Will Be Used In SPC-15's Protocol For Anxiety, PTSD And Stress-Related Disorders
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has announced the advancement of the formulation development of SPC-15. The liquid nasal formulation will be used in SPC-15's protocol for anxiety, PTSD, and stress-related disorders.
August 08, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's announcement of the advancement of SPC-15's formulation could potentially boost investor confidence in the company's product pipeline.
The advancement of SPC-15's formulation development indicates progress in Silo Pharma's product pipeline. This could potentially attract investors who are interested in the company's growth and innovation in the pharmaceutical sector, thereby possibly driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100